SAN FRANCISCO — An investigational quick-release formulation of bromocriptine mesylate produced a 42% reduction in a prespecified combined end point of myocardial infarction, stroke, coronary revascularization, or hospitalization for heart failure or angina in a 52-week study of more than 3,000 patients with type 2 diabetes.
PREVIEW